Healthcare Feb 01, 2021 10:08 AM (GMT+8)
EUROHEALTH learned on February 1 that on January 31, the Hong Kong Stock Exchange officially submitted the PhIP version of the prospectus after the hearing of Novartis health. The first share of China cancer early screening is expected to be officially listed in February, with a plan to raise US $300 million (about HK $2.34 billion). Goldman Sachs (Asia) Limited and UBS Securities Hong Kong Limited (UBS) acted as co sponsors.
According to the prospectus, the IPO fund-raising is mainly used for: large-scale commercialization and further development of Changweiqing;; funding for the continuous sales and marketing of putuoguan;; conducting more clinical evaluation of Changweiqing and putuoguan in different groups; product research and development to further develop the company's pipeline products; potential acquisition or external introduction of candidate products and general company use And so on.
This text is a result of machine translation.